Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

  • Technology appraisal guidance
  • TA272
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Technology Assessments Centre:

  • Cooper K, Frampton G, Mendes D, Bryant J, Vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract, September 2010

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Pierre Fabre

II Professional/specialist and patient/carer groups:

  • Macmillan Cancer Support

  • British Uro-oncology Group (BUG)

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • United Kingdom Oncology Nursing Society

III Other consultees:

  • NHS Bury

  • Department of Health

  • NHS Norfolk

  • Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Institute of Cancer Research

  • Southampton Health Technology Assessment Centre

  • National Institute for Health Research Health Technology Assessment Programme

C The following individuals were selected from clinical specialist nominations from the non-manufacturer consultees and commentators. They gave their expert personal view on vinflunine by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Alison Birtle, Consultant Clinical Oncologist, Royal Preston Hospital, nominated by British Uro-oncology Group – clinical specialist

  • Dr John Chester, Honorary Consultant in Medical Oncology, Leeds Institute of Molecular Medicine, nominated by Royal College of Physicians – clinical specialist

  • Dr Tony Elliott, Consultant Clinical Oncologist, The Christie Hospital, nominated by Royal College of Physicians – clinical specialist

D Representatives from the following manufacturer attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Pierre Fabre